Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruyi Zhenbao pill for knee osteoarthritis
ChiCTR2100052411Phase 4Not yet recruiting
- Sponsor
- Institute of Basic Research in Clinical Medicine
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ruyizhenbao pill in knee osteoarthritis (OA) (4 arms), sponsored by Institute of Basic Research in Clinical Medicine. Primary endpoints: Response rate of VAS pain score at 8 weeks, LANSS score at 8 weeks and 2 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
ruyizhenbao pill
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2100052411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052411.